Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaccine for prevention of mild and moderate-to-severe influenza in children.
Jain VK, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, Cravioto A, Yunus M, Chanthavanich P, Limkittikul K, Kurugol Z, Alhan E, Caplanusi A, Durviaux S, Boutet P, Ofori-Anyinam O, Chandrasekaran V, Dbaibo G, Innis BL. Jain VK, et al. Among authors: boutet p. N Engl J Med. 2013 Dec 26;369(26):2481-91. doi: 10.1056/NEJMoa1215817. Epub 2013 Dec 11. N Engl J Med. 2013. PMID: 24328444 Free article. Clinical Trial.
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
Charland N, Gobeil P, Pillet S, Boulay I, Séguin A, Makarkov A, Heizer G, Bhutada K, Mahmood A, Trépanier S, Hager K, Jiang-Wright J, Atkins J, Saxena P, Cheng MP, Vinh DC, Boutet P, Roman F, Van Der Most R, Ceregido MA, Dionne M, Tellier G, Gauthier JS, Essink B, Libman M, Haffizulla J, Fréchette A, D'Aoust MA, Landry N, Ward BJ. Charland N, et al. Among authors: boutet p. NPJ Vaccines. 2022 Nov 9;7(1):142. doi: 10.1038/s41541-022-00561-2. NPJ Vaccines. 2022. PMID: 36351931 Free PMC article.
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Essink BJ, Shapiro C, Isidro MGD, Bradley P, Pragalos A, Bloch M, Santiaguel J, Frias MV, Miyakis S, Alves de Mesquita M, Berrè S, Servais C, Waugh N, Hoffmann C, Baba E, Schönborn-Kellenberger O, Wolz OO, Koch SD, Ganyani T, Boutet P, Mann P, Mueller SO, Ramanathan R, Gaudinski MR, Vanhoutte N. Essink BJ, et al. Among authors: boutet p. Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18. Hum Vaccin Immunother. 2024. PMID: 39422261 Free PMC article. Clinical Trial.
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.
Levine MZ, Holiday C, Bai Y, Zhong W, Liu F, Jefferson S, Gross FL, Tzeng WP, Fries L, Smith G, Boutet P, Friel D, Innis BL, Mallett CP, Davis CT, Wentworth DE, York IA, Stevens J, Katz JM, Tumpey T. Levine MZ, et al. Among authors: boutet p. Vaccines (Basel). 2022 Nov 1;10(11):1856. doi: 10.3390/vaccines10111856. Vaccines (Basel). 2022. PMID: 36366364 Free PMC article.
Amantadine use in the French prospective NS-Park cohort.
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O; French N. S.-Park network. Fabbri M, et al. J Neural Transm (Vienna). 2024 Jul;131(7):799-811. doi: 10.1007/s00702-024-02772-4. Epub 2024 Apr 5. J Neural Transm (Vienna). 2024. PMID: 38578434
33 results